According to CITIC Securities' research report, the groundbreaking therapeutic HPV vaccine, PRGN-2012, has received marketing approval, effectively bridging the treatment gap in the recurrent respiratory papillomatosis (RRP) field and propelling the innovative therapeutic vaccine industry towards greater prosperity. Overseas, the landscape of therapeutic vaccine research and development is witnessing rapid advancements, with various technology platforms vying for prominence. Notably, significant data is anticipated to be released within the next one to two years, signaling the industry's entrance into a phase of rapid growth. Furthermore, the integration of AI technology is poised to enhance the efficiency of antigen design, thereby accelerating the research, development, and production of vaccines. Investors are encouraged to keep a close eye on enterprises actively engaged in the therapeutic vaccine sector.